Skip to content

Research compound · compound · regulatory review 2026-10-09

P021 (Experimental peptide)

Research-market P21 is associated by vendors with a CNTF-derived neurotrophic peptide; exact identity requires verification.

Experimental P021 is a CNTF-derived peptide with a C-terminal adamantylated glycine modification. This is not a verified synonym for a vendor’s P21 / Peptide 021 material.

Editorial review 2026-10-10. source-curated; clinician review pending.

FDA product
not established
Compounding
not established
Research
investigational
Sport
unknown

What is P021 (Experimental peptide)?

Other names in the library: P021. Experimental P021 is a CNTF-derived peptide with a C-terminal adamantylated glycine modification. This is not a verified synonym for a vendor’s P21 / Peptide 021 material. Listed sizes: no listed milligram sizes in the vendor file. A seller title is a listing. It does not prove the vial matches a paper.

In plain language

P021 (Experimental peptide) is listed here as a compound. Research-market P21 is associated by vendors with a CNTF-derived neurotrophic peptide; exact identity requires verification. Status was checked 2026-10-09. This card reports cited facts. It does not tell you to use P021 (Experimental peptide) or how much to take.

What the evidence says

For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.

Lab or animal research

P021 primary study · PMID 28655344

Female3xTg-AD mice and wild-type controls; behavioral and tissue-analysis groups separate.

Reported findings. Improved spatial/object-location memory and selected neurogenesis, dendritic and synaptic markers were reported.

Nonresponse. Nine-month MAP2 deficit was not prevented; cortical synaptophysin active-versus-vehicle difference was nonsignificant.

Harms. Authors report no weight loss, tumors or signs of pain during approximately18months in mice; no human safety assessment.

Limits. P21/P021 equivalence unresolved. Long preventive mouse treatment does not establish human efficacy or route transfer.

Preparation: Experimental P021: CNTF-derived DGGL with adamantylated glycine, N-terminal acetylation and C-terminal amide; not a verified generic P21 preparation. Route: Oral mouse-feed exposure from age3 through21months; not a human or nasal outcome.

Read original source ↗

Editorial review 2026-10-10. Clinician review pending.

Regulatory status, dated 2026-10-09

FDA product approval

not established. No approval for this exact marketed preparation or claimed wellness indication is established in this source set.

Compounding

not established. Legal compounding eligibility is not established here. Sale or a supplement label does not establish eligibility.

Research

investigational. Transgenic Alzheimer disease mouse models in the cited P021 paper.

Sport

unknown. Not individually verified against current sport rules. Check the exact ingredients with your sport authority.

How long it lasts, how you store it, listed sizes

This entry doesn’t give a duration in hours. No verified human estimate for this exact preparation is supplied. A half-life is not a treatment schedule.

Half-life on file: no single hour value. No verified human estimate for this exact preparation is supplied. A half-life is not a treatment schedule. Follow the label on the vial you hold. This page does not set a throw-away date after you add water.

This card has no units chart until a milligram size is listed.

Risks and mix-ups already on the record

  • Human safety for this exact preparation is incompletely characterized. A lack of reported problems does not establish safety.
  • No complete contraindication list is established for this exact preparation. Review pregnancy, allergies and existing conditions with a clinician.
  • No complete interaction study for this exact preparation is verified. Ingredient combinations are not presumed compatible.

People using PepBear often log: Exact product identity, formulation, dated label and any clinician-directed observations. Record symptoms and changes alongside other medicines, sleep and activity; observations do not establish causation.

Sources

  1. P021 primary study · PMID 28655344 · checked 2026-10-09

Questions people ask

Is P021 (Experimental peptide) FDA-approved?

not established. No approval for this exact marketed preparation or claimed wellness indication is established in this source set.

Does PepBear pick an amount of P021 (Experimental peptide)?

The calculator turns numbers you type into U-100 units. Trial or label amounts stay as cited facts.

Related cards

Discuss the evidence and unresolved identity or safety questions with a licensed clinician. This entry provides no treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.

Optional merchant comparison

Where to buy P021 (Experimental peptide)

Compare the same identity, formulation and format. Blends, oral products and different variants stay separate. A lower price does not establish product quality or medical suitability.

We earn a commission when you buy through PepStar LLC partner links or codes RICHPEP and PEPBEAR. Merchant listings are separate from the evidence and do not establish product quality or medical suitability.

No exact product listing is verified for this identity yet.